Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects (THYMON-10001)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
This protocol represents the second in human study of TUTI-16, and is being conducted to continue to gather safety and human immunogenicity (anti-HIV-1 Tat titers) data of subcutaneously administered TUTI-16.
Condition | Intervention | Phase |
---|---|---|
HIV Infections |
Biological: TUTI-16 (0.2mg) Biological: TUTI-16 (1.0 mg) |
Phase 1 Phase 2 |
Study Type: | Interventional |
Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | Phase I/IIA Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects |
- anti-Tat antibody titer [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]determine the anti-Tat antibody response
- Safety [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]Physical exam, vital signs, local injection site reactions, laboratory parameters, unsolicited and solicited AE reports.
Enrollment: | 15 |
Study Start Date: | September 2010 |
Study Completion Date: | April 2011 |
Primary Completion Date: | April 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: TUTI-16 (0.2mg)
Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.
|
Biological: TUTI-16 (0.2mg)
Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.
|
Experimental: TUTI-16 (1.0 mg)
Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.
|
Biological: TUTI-16 (1.0 mg)
Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.
|
Detailed Description:
HIV-1 Tat protein, a virally encoded toxin, is secreted by HIV-1 infected cells and acts on uninfected cells, rendering them permissive for HIV-1 replication. HIV-1 Tat enhances chronic viral replication and induces immune suppression. Antibodies to Tat inhibit this Tat-mediated transcellular activation in vitro and minimize chronic plasma viremia. HIV-1 Tat activities can be blocked in vitro and in vivo by anti-Tat antibodies.
The Thymon Universal Tat Immunogen (TUTI-16) is a fully synthetic, self-adjuvanting lipopeptide vaccine that is water soluble and administered by subcutaneous injection. In preclinical studies, a priming dose and a three week boost in rats induced a high titer antibody response to the eight known distinct epitope variants of HIV-1 Tat protein. These antibodies block the function of the HIV-1 Tat protein (toxin), which is essential to the maintenance of chronic HIV-1 viremia. Therefore, TUTI-16 has potential as a therapeutic vaccine for HIV-1 in humans.
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Males and Females
- Age ≥18 and ≤50 years at Screening
- HIV negative healthy subjects or HIV-1 seropositive subjects on effective ART for >2 months (undetectable HIV plasma viremia), viral set point before ART >3,000
- CD4+ T-cell count ≥ 500/mm3.
Exclusion Criteria:
- Pregnant/nursing females
- Positive for HBV or HCV
- Acute Herpetic event
- Any clinically significant out-of range laboratory value
- Routine or PRN consumption of immune suppressive medications that the subject is unable or unwilling to discontinue during the study
- Participation in another investigational drug/vaccine study within 30 days preceding the first injection of investigational agent in this study.
No publications provided
Responsible Party: | Thymon, LLC |
ClinicalTrials.gov Identifier: | NCT01144026 History of Changes |
Other Study ID Numbers: | THYMON-10001 |
Study First Received: | June 12, 2010 |
Last Updated: | January 11, 2012 |
Health Authority: | United States: Food and Drug Administration |
Keywords provided by Thymon, LLC:
HIV vaccine lipopeptide |
Tat TUTI-16 THYMON |
Additional relevant MeSH terms:
HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases |
ClinicalTrials.gov processed this record on October 17, 2012